Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000175.xml
Arzneimittelforschung 2012; 62(08): 372-377
DOI: 10.1055/s-0032-1314821
DOI: 10.1055/s-0032-1314821
Original Article
Synthesis and Studies on the Anticonvulsant Activity of 5-alkoxy-[1,2,4]triazolo[4,3-a]pyridine Derivatives
Further Information
Publication History
received 31 December 2011
accepted 02 May 2012
Publication Date:
10 July 2012 (online)

Abstract
In this study, a series of new 5-alkoxy-[1,2,4]triazolo[4,3-a]pyridine derivatives was synthesized and their anticonvulsant activity and neurotoxicity was evaluated with the maximal electroshock and rotarod tests, respectively. The most promising compounds, 3p (5-(4-chlorophenoxy)-[1,2,4]triazolo[4,3-a]pyridine) and 3r (5-(4-bromophenoxy)-[1,2,4]triazolo[4,3-a]pyridine), showed a median effective dose of 13.2 and 15.8 mg/kg and had a protective index value of 4.8 and 6.9, respectively. For exploring the putative mechanism of action, compounds 3n, 3p and 3r were tested in chemically induced models.
-
References
- 1 Loscher W. New visions in the pharmacology of anticonvulsant. Eur J Pharmacol 1998; 342: 1-13
- 2 LeppikI E. Antiepileptic drugs in development: prospects for the near future. Epilepsia 1994; 35 (Suppl. 04) 29-40
- 3 Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996; 42: 531-543
- 4 Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004; 5: 553-564
- 5 Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007; 4: 18-61
- 6 Lin Z, Kadaba PK. Molecular targets for the rational design of antiepileptic drugs and related neuroprotective agents. Med Res Rev 1997; 17: 537-572
- 7 Al-Soud YA, Al-Masoudi NA, Ferwanah Ael R. Synthesis and properties of new substituted 1,2,4- triazoles: potential antitumor agents. Bioorg Med Chem 2003; 11: 1701-1708
- 8 Sun XY, Guan LP, Zhang L et al. Design, synthesis and anticonvulsant activity evaluation of 7-substituted-4H-[1,2,4]triazino[3,4-a]phthalazin-4-one derivatives. J Braz Chem Soc 2009; 20: 826-831
- 9 Guan LP, Sui X, Deng XQ et al. Synthesis and anticonvulsant activity of a new 6-alkoxy-[1,2,4]triazolo[4,3-b]pyridazine. Eur J Med Chem 2010; 45: 1746-1752
- 10 Zhang L, Guan LP, Sun XY et al. Synthesis and anticonvulsant activity of 6-alkoxy-[1,2,4]triazolo[3,4-a]phthalazines. Chem Biol Drug Des 2009; 73: 313-319
- 11 Krall RL, Penry JK, White BG et al. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 1978; 19: 409-428
- 12 Porter RJ, Cereghino JJ, Gladding GD et al. Antiepileptic drug development program. Cleve Clin Q 1984; 51: 293-305
- 13 Bernasconi R, Klein M, Martin P et al. comparison of neurochemical and anticonvulsant effects in mice. J Neural Transm 1988; 72: 213-233
- 14 Arnoldi A, Bonsignori A, Melloni P et al. Synthesis and anticonvulsant and sedative-hypnotic activity of 4-(alkylimino)-2,3-dihydro-4H-1-benzopyrans and -benzothiopyrans. J Med Chem 1990; 33: 2865-2869
- 15 Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 1988; 2: 145-181
- 16 Mokrab Y, Bavro VN, Mizuguchi K et al. Exploring ligand recognition and ion flow in comparative models of the human GABA type A receptor. J Mol Graph Model 2007; 26: 760-774
- 17 Okada R, Negishi N, Nagaya H. The role of the nigrotegmental GABAergic pathway in the propagation of pentylenetetrazol-induced seizures. Brain Res 1989; 480: 383-387
- 18 Olsen RW. GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem 1981; 37: 1-3
- 19 Gale K. GABA and epilepsy: basic concepts from preclinical research. Epilepsia 1992; 33: S3-S12
- 20 Löscher W. 3-Mercaptopropionic acid: convulsant properties, effects on enzymes of the gamma-aminobutyrate system in mouse brain and antagonism by certain anticonvulsant drugs, aminooxyacetic acid and gabaculine. Biochem Pharmacol 1979; 28: 1397-1407